The medical device company completed its total offering of approximately $4.1 million, having made its first sale on April 30, according to the filing.
It took just one investor to complete the financing, although the SEC filing does not specify from where the investment came. The funding includes a finder’s fee of $120,250.
New York-based Pavmed did not specify the intended use of proceeds for the more than $4 million raised. The company recently received FDA 510(k) clearance for its CarpX minimally invasive carpal tunnel device.
Earlier this year, Pavmed confirmed an FDA breakthrough device designation for its Lucid Diagnostics subsidiary’s EsoGuard esophageal DNA test and entered into a clinical trial with the University of Pennsylvania to study Lucid’s EsoCheck esophageal cell collection device.